Literature DB >> 15614159

Modes of benign mechanical transport of breast epithelial cells to axillary lymph nodes.

Nils M Diaz1, Vesna Vrcel, Barbara A Centeno, Carlos Muro-Cacho.   

Abstract

The status of axillary lymph nodes is a key prognostic indicator available for the management of patients with breast cancer. Sentinel lymph node (SLN) evaluation as a predictor of lymph node status has led to increased use of ancillary methods, principally immunohistochemistry, to increase the sensitivity of the SLN biopsy. So-called "occult" micrometastases detected by such methods have led to speculation that some may have reached the SLNs by benign mechanical transport (BMT) rather than a metastatic process. We review evidence suggesting two potential modes of BMT: lymphatic transport of epithelial cells displaced by biopsy of the primary breast tumor and by breast massage-assisted SLN localization. The biopsy techniques under most scrutiny include fine needle aspiration and large-gauge core biopsy. The evidence implicating breast massage prior to SLN biopsy as a mode of BMT has been supported by statistical analysis; however, no method of distinguishing massage-associated cells in SLNs from true occult micrometastases is available. The significance of small epithelial clusters in SLNs is currently unknown. Thus, deviation from current biopsy and SLN-localizing practices is unwarranted.

Entities:  

Mesh:

Year:  2005        PMID: 15614159     DOI: 10.1097/01.pap.0000151267.34438.a1

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  7 in total

1.  Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ?

Authors:  Ashleigh M Francis; Christine E Haugen; Lynn M Grimes; Jaime R Crow; Min Yi; Elizabeth A Mittendorf; Isabelle Bedrosian; Abigail S Caudle; Gildy V Babiera; Savitri Krishnamurthy; Henry M Kuerer; Kelly K Hunt
Journal:  Ann Surg Oncol       Date:  2015-04-24       Impact factor: 5.344

2.  Blue dye injection does not induce dissemination of epithelial cells during SLN procedure in colon cancer patients.

Authors:  Hannes J Larusson; Urs von Holzen; Carsten T Viehl; Farid Rezaeian; Hans-Martin Riehle; Daniel Oertli; Ulrich Guller; Markus Zuber
Journal:  Int J Colorectal Dis       Date:  2014-04-25       Impact factor: 2.571

3.  Real-Time qPCR-Based Detection of Circulating Tumor Cells from Blood Samples of Adjuvant Breast Cancer Patients: A Preliminary Study.

Authors:  Ulrich Andergassen; Michael Zebisch; Alexandra C Kölbl; Alexander König; Sabine Heublein; Lennard Schröder; Stefan Hutter; Klaus Friese; Udo Jeschke
Journal:  Breast Care (Basel)       Date:  2016-06-15       Impact factor: 2.860

4.  Promoter hypermethylation in sentinel lymph nodes as a marker for breast cancer recurrence.

Authors:  Hetty E Carraway; Shelun Wang; Amanda Blackford; Mingzho Guo; Penny Powers; Stacie Jeter; Nancy E Davidson; Pedram Argani; Kyle Terrell; James G Herman; Julie R Lange
Journal:  Breast Cancer Res Treat       Date:  2008-04-11       Impact factor: 4.872

5.  Lymphoscintigraphy and triangulated body marking for morbidity reduction during sentinel node biopsy in breast cancer.

Authors:  Borys R Krynyckyi; Michail K Shafir; Suk Chul Kim; Dong Wook Kim; Arlene Travis; Renee M Moadel; Chun K Kim
Journal:  Int Semin Surg Oncol       Date:  2005-11-08

6.  Core needle biopsy of breast cancer tumors increases distant metastases in a mouse model.

Authors:  Edward Gitau Mathenge; Cheryl Ann Dean; Derek Clements; Ahmad Vaghar-Kashani; Steffany Photopoulos; Krysta Mila Coyle; Michael Giacomantonio; Benjamin Malueth; Anna Nunokawa; Julie Jordan; John D Lewis; Shashi Ashok Gujar; Paola Marcato; Patrick W K Lee; Carman Anthony Giacomantonio
Journal:  Neoplasia       Date:  2014-11-20       Impact factor: 5.715

7.  Isolated tumour cells and micrometastases in intraductal breast cancer: a simple mechanical question in some cases.

Authors:  A Piñero-Madrona; J A Ruiz-Maciá; C Zaragoza-Zaragoza; L Polo-García; J Sola-Pérez
Journal:  Br J Cancer       Date:  2013-03-28       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.